Targeting ATF3 and HNF4A: A Framework for Diagnostic and Therapeutic Repurposing

Overview

This study identifies oxidative phosphorylation and cholesterol homeostasis as critical factors in the pathogenesis of metabolic dysfunction-associated steatohepatitis (MASH). It highlights ATF3 and HNF4A as potential diagnostic and therapeutic targets, with alverine and mecamylamine proposed based on study findings.

Background

Metabolic dysfunction-associated steatohepatitis (MASH) affects approximately 25% of the global population and can lead to severe liver complications, including cirrhosis and hepatocellular carcinoma. Current treatment strategies have limited efficacy. This study explores the role of oxidative phosphorylation and cholesterol homeostasis in MASH progression.

Data Highlights

No numerical data or trial data provided in the source.

Key Findings

• Oxidative phosphorylation and cholesterol homeostasis are implicated in MASH pathogenesis.
• ATF3 and HNF4A were identified as hub variables associated with MASH, with down-regulation and up-regulation, respectively.
• Alverine and mecamylamine are proposed as potential therapeutic agents for MASH treatment.
• The study constructed an OC-associated diagnostic model based on hub variables.
• Machine learning algorithms were utilized to identify diagnostic and therapeutic targets in MASH.

Clinical Implications

The identification of ATF3 and HNF4A as diagnostic and therapeutic targets may facilitate the development of treatment strategies for MASH.

Conclusion

This study provides findings related to oxidative phosphorylation and cholesterol homeostasis in MASH.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. AASLD Announces Update to Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Practice Guidance | AASLD
6. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA
7. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis - PubMed
8. AASLD Announces Update to Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Practice Guidance | AASLD
9. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA
10. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis - PubMed